Main Article Content

Abstract

This study for the diagnosis of thyroid using pcsk9.The current study was conducted on seventy women patients suffering from thyroid disease attending in Center for diabetes and Endocrinology Unit in each of Al-Sadder Teaching Hospital and AL FURAT AL AWSAT Hospital in Al-Najaf province/ Iraq, and during the period from September until December 2017. The sample patients were divided into four study groups: premenopausal hypothyroidism patients group (20), postmenopausal hypothyroidism (15), premenopausal hyperthyroidism patients groups (17), and postmenopausal hyperthyroidism (18). The control group composed of 18 healthy women, also divided into premenopausal control and postmenopausal control.  The results indicated a significant increase (p<0.05) in pcsk9 in hypothyroidism patients compared with the control group, while a significant decrease (p<0.05) in pcsk9 in hyperthyroidism patients compared with the control group.  The results indicated a significant decrease (p<0.05) in pcsk9 in premenopausal hyperthyroidism patients compared with the control group, and a significant decrease (p<0.05) in pcsk9 in postmenopausal hyperthyroidism patients compared with the control group. The results indicated a significant increase (p<0.05) in pcsk9 in premenopausal hypothyroidism patients compared with the control group, and a significant increase (p<0.05) in pcsk9 in the postmenopausal hypothyroidism patients compared with the control group, also a significant increase in pcsk9 in postmenopausal than premenopausal.

Keywords

Pcsk9 Thyroid Menopause

Article Details

How to Cite
Mohammed, H. F., & Jaber, S. H. (2021). Role of Pcsk9 In The Diagnosis Thyroid Disorder in Patient Women. Medical Science Journal for Advance Research, 2(1), 29–34. https://doi.org/10.46966/msjar.v2i1.16

References

  1. Abifadel, M .; Varret, M.; Rabes, J. P.; Allard, D.; Ouguerram, K.; Devillers, M.; Cruaud, C.; Benjannet, S.; Wickham, L.; Erlich, D.; Derre, A.; Villeger ,L.; Farnier, M.; Beucler, I.; Bruckert, E.; Chambaz, J.; Chanu, B.; Lecerf, J.M.; Luc, G.; Moulin. P.; Weissenbach, J.; Prat , A .; Krempf, M.; Junien, C.; Seidah, N.G.; and Boileau, C.(2003). Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat. Genet., (34):154-160.
  2. Abulaiti Alimujiang.; Li, B.; Zhang, L. and et al. (2016).Relationship between subclinical hypothyroidism and coronary artery disease [J]. Medical Journal of the Chinese People’s Armed Police Force.,(27): 221-224.
  3. A-DeVay, R. M.; Shelton, D. L. and Liang H.(2013). Characterization of proprotein convertase subtilisin/kexin type 9 (PCSK9) trafficking reveals a novel lysosomal targeting mechanism via amyloid precursor-like protein 2 (APLP2). J. Biol. Chem., (288):10805–10818.
  4. Alexandre, C.; Andermann, M.L. and Scammell, T.E. (2013). Control of arousal by the orexin neurons. Current opinion in neurobiology. (23):752-759.
  5. Almandoz, J. P. and Gharib, H. (2012). Hypothyroidism: etiology, diagnosis, and management. Med. Clin. North. Am., (96):203-221.
  6. Almontashiri, N. A.; Vilmundarson, R. O.; Ghasemzadeh, N. Dandona, S.; Roberts, R.; Quyyumi, A. A.; Chen, H. H., and Stewart, A. F. (2014). Plasma PCSK9 levels are elevated with acute myocardial infarction in two independent retrospective angiographic studies.
  7. Antonica , F.; Kasprzyk, D. F.; Opitz ,R.and et al.(2012). Generation of functional thyroid from embryonic stem cells. Nature.,(491):66-71.
  8. Ason, B.; Tep, S.; Davis, H. R.; Jr.; Xu, Y.; Tetzloff, G.; Galinski, B.; Soriano, F.; Dubinina, N.; Zhu, L.; Stefani, A.; Wong, K. K.; Tadin- Strapps, M.; Bartz, S. R.; Hubbard, B.; Ranalletta, M.; Sachs, A. B.; Flanagan, W. M.; Strack, A. and Kuklin, N. A. (2011). Improved efficacy for ezetimibe and rosuvastatin by attenuating the induction of PCSK9. J. Lipid. Res., (52):679–687.
  9. Åsvold, B. O.; Vatten, L. J.; Midthjell, K. and Bjøro, T.(2012). Serum TSH within the reference range as a predictor of future hypothyroidism and hyperthyroidism: 11-year follow-up of the HUNT Study in Norway. J Clin Endocrinol Metab.,(97):93–99.
  10. Awan, Z.; Seidah, N. G.; MacFadyen, J. G.; Benjannet, S.; Chasman, D. I.; Ridker, P. M. and Genest, J. (2012). Rosuvastatin, proprotein convertase subtilisin/Kexin type 9 concentrations, and LDL cholesterol response: the JUPITER trial. Clin. Chem. (58):183–189.
  11. Baass, A.; Dubuc, G.; Tremblay, M.; Delvin, E. E.; O’Loughlin, J.; Levy, E.; Davignon, J. and Lambert, M. (2009). Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents. Clin. Chem., (55):1637–1645.
  12. Baranowska, B.; Wolinska-Witort, E.; Martynska, L.; Chmielowska, M. and Baranowska-Bik, A.(2005) Plasma orexin A, orexin B, leptin, neuropeptide Y (NPY) and insulin in obese women. Neuro. Endocrinol. Lett., 26(4):293–296.
  13. Barrett, K. E.; Barman, S. M.; Boitano, S. and Brooks, H.L. (2016). Basic Concepts of Endocrine Regulation. Ganong's Review of Medical Physiology. 25th ed. McGraw Hill Education., 298-306.
  14. Bass, J. and Takahashi, J. S. (2010). Circadian integration of metabolism and energetics. Science., (330) :1349–1354.
  15. Chieffi, S.; Carotenuto, M.; Monda, V.; Valenzano, A.; Villano, I.; Precenzano, F.; Tafuri, D.; Salerno, M.; Filippi, N.; Nuccio, F.; Ruberto, M.; De Luca, V.; Cipolloni, L.; Cibelli, G.; Mollica, M.P.; Iacono, D.; Nigro, E.; Monda, M.; Messina, G. and Messina, A.( 2017). Orexin system: the key for a healthy life. Front. Physiol., (8). 357.
  16. Ghosh, M.; Galman, C.; Rudling, M. and Angelin, B. (2015). Influence of physiological changes in endogenous estrogen on circulating PCSK9 and LDL cholesterol. J. Lipid Res. (56):463-9.
  17. Graeter, L. J.; Hertenstain, E. G.; Accurso, C. E.; Elizabirth, G.; Charity, E. and Labiner, G. H.(2015).Medical laboratory science examination review.1st ed . Elsvier .,(8): 246-248.
  18. Haarburge, D.(2012). Thyroid disease: thyroid function tests and interpretation. C.M.E.J. (30).
  19. Hampton, E.N. Knuth,M.W. Li, J. Harris, J.L.; Lesley, S.A. and et al.(2007). The self-inhibited structure of full-length PCSK9 at 1.9 A reveals structural homology with resistin within the C-terminal domain. Proc Natl Acad Sci U S A., (104):14604–9.
  20. Han, T.; Sattar, N. and Lean, M. (2006). ABC of obesity Assessment of obesity and its clinical Implications. British Medical Journal, 333: 695-698.
  21. Pirillo, A. and Catapano, A. L.(2015). Berberine, a plant alkaloid with lipid- and glucose-lowering properties: From in vitro evidence to clinical studies. Atherosclerosis. (243):449-61.
  22. Poli, F.; Plazzi, G.; Dalmazi, G. and et al.(2009). Body Mass Index- Independent Metabolic Alterations in Narcolepsy with Cataplexy. Sleep .,(32): 1491–1497.
  23. Pritzer, D. N.; Abbas, A.K and Aster J. C. (2015). Endocrine system. Textbook of Pathologic basis of disease. 9th ed. Saunders Elsevier. Inc., (24): 1083-1093.
  24. Rabon, S.; Burton, A.M. and White, P.C. (2016). Graves' Disease in Children: Long Term Outcomes of Medical Therapy. Clin. Endocrinol (Oxf).